Jame Abraham, MD, FACP

DESTINY 05 trial - in high risk her - 2 positive #breastcancer - 53% reduction in invasive disease free survival with TDXd - @NSABPFoundation @myesmo.bsky.social @oncoalert.bsky.social ! Honored to be part of the study ! @clevelandclinic.bsky.social

It was a beautiful and blessed weekend for the Abraham family—our son Abel married Kathryn!

Artificial Intelligence in Oncology Jame Abraham, MD, Chair of the Department of Hematology & Medical Oncology at Cleveland Clinic Cancer Institute, joins the Cancer Advances Podcast to discuss how artificial intelligence (AI) is transf...

From improving efficiency to advancing research, AI is transforming oncology. I joined @Shepard Dale on the @CleClinicMD Cancer Advances podcast to discuss what this means for patients and providers. #CleClinicCancer cle.clinic/41OwRO8

David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87

David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87 www.nytimes.com/2025/09/07/s...

BioNTech's HER2 ADC beats Roche's Kadcyla in phase 3 breast cancer trial BioNTech’s HER2 antibody-drug conjugate has beaten< | BioNTech’s HER2 antibody-drug conjugate has beaten Roche’s Kadcyla in a phase 3 breast cancer trial, positioning the company’s partner Duality Bio...

www.fiercebiotech.com/biotech/bion...

It is Bike VeloSano weekend in #cleveland Thank you for coming together to raise money for cancer research @clevelandclinic.bsky.social ! Science and research saves lives !!

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with a... Allocation to 5 further years of AIT reduced subsequent distant recurrence rates by about a quarter despite substantial non-adherence. Longer follow-up would have been needed to help assess directly a...

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy - The Lancet www.thelancet.com/journals/lan...

Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents | JCO Oncology Practice Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases that are prognostically stratified into lower-risk (LR-MDS) and higher-risk MDS on the basis of the International Prognostic Scori...

ascopubs.org/doi/10.1200/... @ascocancer.bsky.social

We are excited to welcome Dr. Santhosh Rao as the Medical Director of the HemOnc team @ClevelandClinic Akron General! In addition to general oncology - he will be focusing on building a Genito Urinary Medical Oncology Program in @ClevelandClinic Southern Market

Pleaase join me in congratulating Nancy Musoke M.D, third year HemOnc Fellow Cleveland Clinic the reciepient of CLL Society’s 2025 Integrative Medicine Award. "Curcumin, Exercise and Placebo Effects on CLL / SLL Progression and Immune Function

Human Epidermal Growth Factor Receptor 2 Positivity a Moving Target in the Era of Antibody-Drug Conjugates | JCO Oncology Practice ascopubs.org/doi/10.1200/... @oncoalert.bsky.social

Outstanding talk on AI in healthcare by @neilmehtamd.medsky.social @clevelandclinic.bsky.social Artificial intelligence summit!

Wonderful to be part of one of the best cancer programs in the country as per @newsweek.com rankings.newsweek.com/americas-bes... @clevelandclinic.bsky.social

My conversations with Dr. Grobmyer of @clevelandclinic.bsky.social @ascopost.bsky.social ascopost.com/news/june-20...

Congratulations to the outstanding group of fellows graduating from @clevelandclinic.bsky.social Hematology and Medical Oncology Department in 2025! We are so proud of them and wish them all the best !!

meetings.asco.org/abstracts-pr...

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer | NEJM Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial conducted at 55 centers, ...

www.nejm.org/doi/full/10....

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer @nejm.org @ascocancer.bsky.social @clevelandclinic.bsky.social

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer | NEJM Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer....

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

Wonderful to be part of the editorial board members of @ascopost.bsky.social ! #1 oncology news paper in the world ! Voice of @ascocancer.bsky.social

Thank you @theaacr.bsky.social for your leadership in advocating for cancer research! @ascocancer.bsky.social

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer | NEJM In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo plus...

www.nejm.org/doi/full/10.... @oncoalert.bsky.social

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer | NEJM Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin–proteasome system. In this phase 3, open-label, randomized tria...

www.nejm.org/doi/full/10.... @oncoalert.bsky.social

Looking forward to seeing you at @ascocancer.bsky.social 2025 meeting - please visit @clevelandclinic.bsky.social booth

We are looking for exceptional doctors to join our HemOnc team - Ohio/ Florida - if you are attending @ascocancer.bsky.social meeting please reach out jobs.clevelandclinic.org/job/16715724...

Thanks to the Canton community for coming together to raise money for supporting women undergoing cancer treatment @clevelandclinic.bsky.social Mercy Hospital

Glory Days: Celebrating Two Decades of Advances in #Cancer Care on the 20th Anniversary of JCO Oncology Practice.

ascopubs.org/doi/full/10....

@ascocancer.bsky.social
#CancerCare #FinancialToxicity #CancerResearch
@ethicsdoctorp.bsky.social @fumikochino.bsky.social @jameabraham.bsky.social

Excellent review article by @ptarantinomd.bsky.social on redefining Her-2 testing @ethicsdoctorp.bsky.social @acochran12733.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social

Nurses are the backbone of compassionate care! We are privileged to have some of the best nurses in the world @clevelandclinic.bsky.social #happynursesweek!

Looking forward to the oncology update in June 18th 2025 @clevelandclinic.bsky.social www.clevelandclinicmeded.com/live/courses...